1.	Aromatase Inhibitor Clinical Trial Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 40 to 70 Sponsor: NIGMS Protocol IDs: 0412-14, UO1-GM61373-06, NCT00228956
2.	Pharmacogenetics as a Predictor of Toxicity in Pre-Menopausal Women Receiving Doxorubicin and Cyclophosphamide in Early Breast Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 45 Sponsor: Other Protocol IDs: 0501-37, NCT00352872
3.	Clinical and Histologic Evaluation of Acellular Dermal Matrix Substitute in Breast Reconstruction Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 26658, NCT00872859
4.	A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6 Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO# 08-1373, NCT00900744
5.	Lymphedema Following Hand/Wrist Surgery in Women Post Axillary Node Dissection Phase: Phase IV Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-09-14B, NCT00984269
6.	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: 20050113, NCT00243685
7.	Phase II/III Randomized Study of Neoadjuvant Therapy Comprising Exemestane Versus Letrozole Versus Anastrozole in Postmenopausal Women With Estrogen Receptor Positive Stage II or III Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: Postmenopausal Sponsor: NCI Protocol IDs: ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
8.	Phase II/III Study of Neoadjuvant Therapy Comprising Capecitabine and Paclitaxel (Albumin-Stabilized Nanoparticle Formulation) (Abraxane®) in Women With Previously Untreated, Unresected, Stage II-IIIB Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WHC-MRI-GU-2006-097, NCT00397761
9.	Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer Phase: Phase III, Phase II Type: Treatment Status: Active Age: 65 and over Sponsor: Other Protocol IDs: 0120070323, NCT00698971
10.	Phase III Randomized Study of Adjuvant Chemotherapy in Women With Radically Resected Loco-Regional Relapsed Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: IBCSG-27-02, BIG-1-02, EU-20320, NCT00074152, NSABP-B-37, EUDRACT-2005-001484-64
11.	A Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DOXIL-BCA-3001, NCT00091442
12.	Phase III Randomized Study of Adjuvant Zoledronate Versus Clodronate Versus Ibandronate in Women With Resected Primary Stage I-III Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0307, NCCTG-SWOG-S0307, ECOG-SWOG-S0307, NSABP-SWOG-S0307, CALGB-SWOG-S0307, CAN-NCIC-SWOG-S0307, S0307, NCT00127205
13.	Phase III Randomized Study of Adjuvant Combination Chemotherapy and Hormonal Therapy Versus Adjuvant Hormonal Therapy Alone in Women With Previously Resected Axillary Node-Negative Breast Cancer With Various Levels of Risk for Recurrence (TAILORx Trial) Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI Protocol IDs: ECOG-PACCT-1, SWOG-ECOG-PACCT-1, CALGB-ECOG-PACCT-1, NCCTG-ECOG-PACCT-1, NSABP-ECOG-PACCT-1, ACOSOG-ECOG-PACCT-1, CAN-NCIC-MAC12, PACCT-1, NCT00310180, TAILORx
14.	Phase III Randomized Study of Fulvestrant With or Without Lapatinib Ditosylate in Postmenopausal Women With Stage III or IV Hormone Receptor-Positive Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40302, NCT00390455
15.	A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181114, NCT00428220
16.	Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer Phase: Phase III Type: Behavioral study, Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: OCOG-2007-LISA, NCT00463489
17.	ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF106708, BIG 2-06/N063D/MAC13, NCT00490139
18.	A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2-Positive Metastatic Breast Cancer (CLEOPATRA) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TOC4129g, WO20698, NCT00567190
19.	Phase III Randomized Study of Tamoxifen Citrate or Letrozole With Versus Without Bevacizumab in Women With Hormone Receptor-Positive Stage IIIB-IV Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40503, CALGB 40503, NCT00601900
20.	Phase III Randomized Study of Adjuvant Combination Chemotherapy Followed By Docetaxel Versus Ixabepilone in Women With Completely Resected Nonmetastatic, Poor-Prognosis Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other, Pharmaceutical / Industry Protocol IDs: FNCLCC-PACS-08/0610, FNCLCC-PACS 08/0610 – TavIx, EU-20804, FNCLCC-Tavlx, BMS-FNCLCC-PACS-08/0610, AMGEN-FNCLCC-PACS-08/0610, NCT00630032
21.	BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NSABP B-44-I, CIRG (TRIO) 011, Roche BO20906, BETH, NCT00625898
22.	Phase III Randomized Study of Neoadjuvant Paclitaxel in Combination With Trastuzumab (Herceptin®) and/or Lapatinib Ditosylate in Patients With HER2-Positive Resectable Stage II or III Breast Cancer Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40601, CALGB 40601, NCT00770809
23.	Phase III Randomized Study of Paclitaxel Versus Paclitaxel Albumin-Stabilized Nanoparticle Formulation Versus Ixabepilone in Combination With Bevacizumab in Patients With Locally Recurrent, Stage IIIB or IV Breast Cancer Phase: Phase III Type: Natural history/Epidemiology, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-40502, CALGB 40502, NCT00785291
24.	Study Evaluating Neratinib vs Lapatinib Plus Capecitabine for ErbB2 Positive Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3144A2-3003, NCT00777101
25.	A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCRI BRE 145, TITAN, NCT00789581